年9月29日,ESMO年会进入第三天,本届年会结直肠癌领域的第二重要的内容-壁报讨论在下午结束,组委会从一共近篇投稿摘要中筛选了10篇最重要的进行了讨论点评,一共分三部分,大部分摘要都体现了精准医学在临床实践中的应用,给人印象最深的当属第一部分的三个有关HER2扩增的研究,让人隐约能预见mCRC治疗的下一个精准医学时代可能将会是“HER时代”,不管怎样,本次ESMO年会,我已经开始嗅到“她”的味道。 ESMO年会结直肠癌领域壁报讨论专场(PosterDiscussion)议程 -时间:-09-29,15:00-16:15 -地点:CordobaAuditorium(Hall7) -内容: 1)第一部分:LBA35,LAB36,PD,PD a)LBA35–HERACLES-8研究:帕妥珠单抗联合T-DM1治疗HER2阳性mCRC的II期研究(PhaseIIstudyofpertuzumabandtrastuzumab-emtansine(T-DM1)inpatientswithHER2-positivemetastaticcolorectalcancer:TheHERACLES-B(HER2AmplificationforColo-rectaLcancerEnhancedStratification,cohortB)trial) b)LBA36–CAPTEM研究最终结果:卡培他滨联合替莫唑胺(CAPTEM)对比FOLFIRI治疗RAS突变、MGMT甲基化mCRC的II期研究(RandomizedphaseIIstudyofCAPTEMversusFOLFIRIinRASmutated,MGMTmethylatedmetastaticcolorectalcancer(mCRC):Finalanalysis,tumourbiomarkersandmethylatedctDNA) c)PD–TRIUMPH研究:曲妥珠单抗联合帕妥珠单抗治疗肿瘤组织或ctDNA中HER2扩增mCRC的II期试验:GOZILA子研究(PrimaryefficacyofaphaseIItrialoftrastuzumab(T)andpertuzumab(P)inpatients(pts)withmetastaticcolorectalcancer(mCRC)withHER2(ERBB2)amplification(amp)intumourtissueorcirculatingtumourDNA(ctDNA):AGOZILAsub-study) d)PD–MOUNTAINEER研究初步结果:曲妥珠单抗联合tucatinib(突卡替尼,即ONT-,一种HER2高选择性口服小分子激酶抑制剂)治疗HER2扩增mCRC的试验(TrastuzumabandtucatinibforthetreatmentofHER2amplifiedmetastaticcolorectalcancer(mCRC):InitialresultsfromtheMOUNTAINEERtrial) 2)第二部分:PD,PD,PD,PD a)PD-CCTGCO.26研究更新:克隆性和DNA修复突变对MSS型mCRC患者血浆肿瘤突变负荷(pTMB)及免疫治疗疗效的影响(ImpactofclonalityandDNArepairmutationsonplasmatumourmutationburden(pTMB)andimmunotherapyefficacyinmicrosatellitestable(MSS)metastaticcolorectalcancer(mCRC)inCCTGCO.26) b)PD–甲基化ctDNA对mCRC疗效的早期预测价值(EarlyidentificationoftreatmenteffectbymethylatedcirculatingtumourDNAinmetastaticcolorectalcancer) c)PD–结直肠癌患者中移行扩增分子标签与EGFR单抗疗效的关系(Associationbetweentransit-amplifyingsignatureandout致力于白癜风的研究中西医诊疗白癜风区别 |